News
AZ, Daiichi Sankyo cue up TROP2 drug filing in breast cancer
Armed with the first phase 3 data for their TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan as a second-line treatment for breast cancer, AstraZeneca
